Eli Lilly and Co., US5324571083

Nov. 12 China approval: Eli Lilly and Co. stock slips 1.82% to EUR 1,296.20

Published on 11/17/2026 at 07:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
China approved Lilly's oral weight-loss medicine orforglipron on November 12, 2026. On Xetra, the stock closed at EUR 1,320.20 on Monday, November 16, 2026.

China approval shapes Lilly outlook

  • China approved orforglipron for weight management on November 12, 2026.
  • The oral GLP-1 drug gives Lilly an early position in a major obesity market.
  • A type 2 diabetes application remains under review in China.
Eli Lilly and Co., US5324571083, Illustration mit AI erstellt.

Eli Lilly and Co. stock traded at EUR 1,296.20 on Lang & Schwarz at 07:53 CET on Tuesday, November 17, 2026, 1.82 percent below the Xetra close of Monday, November 16, 2026, at EUR 1,320.20.

China approved Eli Lilly's oral GLP-1 medicine orforglipron for weight management on November 12, 2026, according to Pharmaphorum. The approval makes the treatment the first oral GLP-1 medicine cleared in China for weight management, according to Lilly's Chinese subsidiary.

China expands Lilly's obesity opportunity

Eli Lilly develops and commercializes medicines worldwide. Orforglipron, marketed as Foundayo in the United States and the United Kingdom, adds an oral option to Lilly's weekly tirzepatide injection in China. The company said a separate application for use in type 2 diabetes remains under review by China's National Medical Products Administration.

The Chinese market offers Lilly a new commercial channel in obesity care, while the launch is being prepared through authorized healthcare and pharmaceutical institutions. Pricing and a launch date were not disclosed in the cited report.

Broader market context remains tied to the S&P 500.

More news and analyses on Eli Lilly and Co. stock

Disclaimer...
en | US5324571083 | ELI LILLY AND CO. | boerse | 70525136 | bgmi